echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Plasma particles affect endothelial cells differently when patients with sickle cell disease have different effects on endothelial cells

    Blood: Plasma particles affect endothelial cells differently when patients with sickle cell disease have different effects on endothelial cells

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Particles (MPs) are submicron extracellular vesicles that can be detected in large quantities in the blood circulation of patients with sickle cell anemia (SS)Several studies have studied the biological effects of MPs in vitroGarnier et alanalyzed for the first time the effects of circulating MPs on endothelial cells (ECs) in 60 patients with sickle cell disease (SCD)SCD MPs were collected and compared with MPs isolated from healthy individuals, in addition to plasma MPs in SS patients with hydroxyurea (HU) and 2 years after treatment, as well as plasma MPs in SS patients with vascular obstruction and stable stateSS MPs increase mRNA and protein levels of endothelial cell ICAM-1 and neutrophil adhesion compared to AA MPsICAM1 overexpression is mainly caused by MPs derived from red blood cells, MPs derived from platelets have no such induction effect;had a reduced ability to induce endothelial cells to promote inflammatory manifestations in SS patients after HU treatment compared to MPs collected before treatmentConversely, MPs released during vascular obstruction can increase ICAM-1 and neutrophil adhesion levels in a PS-dependent manner compared to MPs collected in a stable stateIn addition, closed anti-ICAM-1 antibodies can eliminate neutrophil adhesion, this study proves that MPs play an important role in SCH pathophysiology by triggering the pro-inflammatory phenotypes of endothelial cells, revealing a new model of HU's role, and suggesting potential new therapies, namely membrane-linked protein V and anti-ICAM-1 antibodies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.